Originally published In Press as doi:10.1074/jbc.M002991200 on May 2, 2000
J. Biol. Chem., Vol. 275, Issue 33, 25381-25390, August 18, 2000
Chemically Regulated Transcription Factors Reveal the
Persistence of Repressor-resistant Transcription after Disrupting
Activator Function*
Stephen R.
Biggar and
Gerald R.
Crabtree
From the Department of Developmental Biology and Department of
Pathology, Stanford University Medical School,
Stanford, California 94305
Received for publication, April 9, 2000
 |
ABSTRACT |
Control of gene expression often requires that
transcription terminates rapidly after destruction, inactivation, or
nuclear export of transcription factors. However, the role of
transcription factor inactivation in terminating transcription is
unclear. We have developed a means of conducting order of addition and
co-occupancy experiments in living cells by rapidly exchanging proteins
bound to promoters. Using this approach, we found that, following
specific disruption of activator function, transcription from active
promoters decayed slowly, persisting through multiple cell divisions.
This persistent transcriptional activity raised the question of what mechanisms return promoters to inactive states. By exchanging or
directing co-occupancy of protein complexes bound to a promoter, we
found that the transcriptional inhibitor, Ssn6-Tup1, lost its effectiveness as a repressor following activator dissociation. Similar
experiments with another repressor, the histone deacetylase Sin3-Rpd3,
reinforced this distinction between repression in the presence and
absence of an activator. These results suggest that although repressors
such as Ssn6-Tup1 and Sin3-Rpd3 prevent activation of gene expression,
other mechanisms of repression return promoters to inactive states
following the dissociation or inactivation of a transcriptional activator.
 |
INTRODUCTION |
Although many mechanisms of transcriptional regulation have been
proposed, perhaps the most general and well documented is the
recruitment of transcriptional activators to sites on DNA (for review
see Ref. 1). The effectiveness of recruitment seems surprising; because
the mammalian genome encodes perhaps 10,000 transcriptional activators
(61), random interactions of activators with promoters would be
expected based on a high cumulative concentration of activators within
the nucleus. Furthermore, activators often require only short stretches
of DNA for stable binding in vitro, and therefore a
background of transcription would be expected because of nonspecific
DNA binding by activators. The fact that such a background is not
generally observed suggests that repressors and/or chromatin prevents
transcription resulting from nonspecific functions of the many
activators in the nucleus. Alternatively, recruitment or displacement
of an activator might actually be remarkably precise regulatory
mechanisms, and repressors and chromatin serve other purposes.
Controlling the proximity of an activator to DNA may also be important
in inactivating transcription in response to external stimuli. In many
cases, activators are displaced from DNA after post-translational
modification of the activator, for example, by phosporylation. In other
cases, transcription factors are exported from the nucleus
(NF-ATc and Pho4) or degraded (Swi5, NF
B) following the
termination of signaling (62-64). In each case, the promoter is left
without the function of a critical activator. Disrupting activators
coincides with transcriptional down-regulation over fairly short
periods of time. These rapid responses generate the tightly controlled
patterns of expression of cell cycle-regulated genes and direct a well
ordered sequence of gene expression in lymphocytes following receptor
activation. A priori, mechanisms that lead to the
termination of transcription could be as simple as removal of the
activator or may include additional repressor mechanisms dedicated to
returning genes to their inactive states. We set out to establish
whether specifically disrupting activator function sufficed to rapidly
silence gene expression.
Transcriptional repressors inhibit gene expression. Interestingly,
promoters lacking binding sites for transcriptional activators fail to
drive expression in vivo, suggesting that the presence or
absence of activators, and not transcriptional repressors, determines
which genes are turned on and off. Instead of preventing gene
expression, repressors may expedite the silencing of active promoters.
Consistent with this possibility, stimuli that silence ongoing
expression lead to the simultaneous displacement of an activator and
recruitment of a repressor at several promoters (2-4). In these
examples, repressors are functionally positioned to quickly shut off
transcription. Thus we wanted to explore this potential role of
transcriptional repressors in more detail.
The activities of transcription factors require, in many cases, the
simple act of localizing these proteins to sites within promoters (5).
We exploited this principle to develop methods of regulating the
activities of transcriptional activators and repressors by controlling
their interactions with DNA. The interactions generated by
cell-permeable compounds such as FK506, and rapamycin permitted the use
of these drugs to control transcription factor activity in living cells
(1). In the present study we have made use of the reversibility of
FK506-driven interactions to activate and inactivate the function of a
transcriptional activator in vivo. The properties of FK506
and rapamycin allowed us to further develop this system and perform
experiments in which activators and repressors acted either
sequentially or simultaneously at the same promoter. Using these
approaches we showed that transcription shuts off slowly following the
disruption of activator function. The remaining transcriptional
activity was relatively insensitive to suppression by Sin3-Rpd3 and
Ssn6-Tup1, indicating that these repressors are dedicated to preventing
activation from a promoter but do not serve to reset promoters to
inactive states after activator displacement.
 |
MATERIALS AND METHODS |
Yeast Strains and Plasmids--
YDF6 (Mata
fpr1::ADE2 TOR1-1 leu2-3, 112 ura3-52 trp1-901
his3-
200 ade2-101 gal4
gal80d
URA3::GAL-LacZ GAL-LacZ LY2::GAL-HIS3), and
the plasmids expressing the
Gal4BD-FKBP12,1 Gal4AD-CN,
and Gal4AD-FRB fusions (pGal4BD/FKBP, pSE-CN2b, and pACT-FRAP,
respectively) were described previously (1, 56). YSB7 (Mat
leu2-3, 112 ura3-52 trp1-901 his3-
200 ade2-101
gal4
gal80
fpr1
::ADE2 TOR1-1
LY2::GAL-HIS3 GAL-LacZ) was derived from a cross between
YDF6 and YJO-Z (59). The resulting diploids were sporulated and
haploids carrying the fpr1
::ADE2,
TOR1-1, and LY2::GAL-HIS3 alleles were
selected. YSB6 (Mat
TOR1-1 ade2-1 ade3
22
his3-11, 15 leu2-3, 112 trp1-1 can1-100 ura3-1 GAL4 GAL80 MIG1)
was generated by transforming YMW1 (Mat
ade2-1
ade3
22 his3-11, 15 leu2-3, 112 trp1-1 can1-100 ura3-1
GAL4 GAL80 MIG1) with the NcoI-KpnI
containing the TOR1-1 mutation and selecting rapamycin-resistant colonies. Mutations in TOR1 were
distinguished from FRP1 mutations by testing the ability of
an FRP1 expression plasmid to restore rapamycin sensitivity.
YSB9 was generated by transforming YSB7 with pMIG1-
2 (26) cut with
SacI.
The FRB overexpression vector, pYSB100-FRB45, expresses the 45-kDa FRB
domain of the yeast Tor1 (amino acids 1765-2158) from the yeast
GPD1 promoter. The calcineurin expression plasmid, pCNA/B, expresses the murine calcineurin A subunit (amino acids 12-394) fused
to the SV40 nuclear localization signal and the influenza hemagglutinin
epitope tag and expressed from the GPD1 promoter. pCNA/B, a
high copy number plasmid, also carries a yeast genomic fragment
containing the yeast calcineurin B subunit expressed from its
endogenous promoter. YCpG4/FK is a single copy plasmid (unlike
pGal4/FKBP) expressing Gal4BD-FKBP12 from the ADH1 promoter. The FRB-Ssn6 expression construct, pFRAP-Ssn6, expressed the entire open reading frame of SSN6 fused to the FRB domain of FRAP
(amino acids 2012-2114) (8) from the GPD1 promoter on a
single-copy URA3 plasmid. The FRB-Sin3 expression construct,
pFRAP-Sin3, expressed the open reading frame of SIN3 fused
to the FRB domain of FRAP from the GPD1 promoter on a
single-copy URA3 plasmid. Details of the construction of
these plasmids are available upon request.
Analysis of Gene Expression--
-Galactosidase assays were
performed as described previously (1). Total yeast RNA was isolated as
described (60). To minimize the amounts of rapamycin and FK506
necessary to conduct these experiments, cells in log phase were
concentrated 3-fold in fresh medium at 30 °C. Under these
conditions, cells continued to divide exponentially for at least 7 h (data not shown). For unknown reasons, rapamycin competes with FK506
more efficiently at higher cell densities (data not shown). Thus a
300-fold excess of rapamycin completely eliminated FK506-induced
transcriptional activation under these conditions. mRNA levels were
determined by Northern blotting using antisense RNA probes as described
(1). RNA levels were quantitated by PhosphorImager analysis using
ImageQuant software. The HIS3 probe recognized an endogenous
message whose levels corresponded well to
-actin (ACT1)
message levels (data not shown). This band was therefore used a control
for RNA loading.
To arrest cells in G1 phase of the cell cycle, cells were
grown into mid-log phase in minimal glucose medium, spun, and
resuspended in rich glucose medium (pH 6.0) containing 50 ng/ml FK506
and 40 µg/ml
-factor for 3 h at 30 °C. >95% of cells
were schmoos at this time. Cells were washed twice with fresh
YPD and split into two cultures. Fresh
-factor was added to one of
the cultures, and both were treated with 15 µg/ml rapamycin. >95%
of cells budded and divided after washing and growth in the absence of
A-factor, whereas cells maintained in A-factor retained schmoo
morphology (data not shown).
 |
RESULTS |
Ligand-regulated Protein Exchange at Promoters in Vivo--
To
study the roles of activators and repressors in controlling gene
expression, a method of inducibly and reversibly localizing proteins to
promoters in living cells was developed (1). This strategy was based on
the use of synthetic ligands or chemical inducers of dimerization and
takes advantage of the fact that, in many cases, recruitment of
transcription factors to DNA suffices to activate their function (5,
6). The specific approach in this study employed two cell-permeable
compounds, FK506 and rapamycin, which both bind the FK506-binding
protein (FKBP) with nanomolar affinities
(7-9). The composite surface formed by FKBP-FK506 or FKBP-rapamycin
binds either calcineurin or an FKBP-rapamycin binding domain (FRB),
respectively. In cells expressing the Gal4 DNA-binding domain (Gal4BD)
fused to FKBP12, FK506 induces the association of FKBP12 with
calcineurin (CN) at promoters containing Gal4-binding sites. By
creating a version of calcineurin fused to the Gal4 activation domain
(Gal4AD-CN), we generated a means of using FK506 to recruit an
activator to a promoter and activate transcription (Fig.
1A) (1). Rapamycin, which
dissociates FK506-mediated interactions by competing for binding to
FKBP, was then used to displace the activator from Gal4BD-FKBP12 and
the promoter.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1.
Using FK506 and rapamycin to regulate the
function of transcriptional activators and repressors in
vivo. A, schematic representation of FK506-
and rapamycin-regulated recruitment and displacement, respectively, of
a Gal4 activation domain-calcineurin A (Gal4AD-CN) fusion at promoters
bound by Gal4BD-FKBP. B, in the presence of a FRB-repressor
fusion, rapamycin also recruits the transcriptional repressor to the
promoters. Schematic shows co-occupancy and ordered addition of a
transcriptional activator and a transcriptional repressor at the same
promoter through the use of FK506 and rapamycin.
|
|
Using a related approach, fusions between transcriptional repressors
and the FRB domain permitted the use of rapamycin to recruit repressors
and thereby inhibit transcription from promoters containing
Gal4-binding sites. In yeast expressing Gal4BD-FKBP12, Gal4AD-CN, and
FRB-repressor fusion proteins, FK506 and rapamycin were used to
regulate the activities of both activators and repressors at the same
promoter. In this way, order of addition experiments, in which an
activator and a repressor act sequentially, and co-occupancy experiments, in which the activator and repressor act simultaneously, were conducted in vivo (Fig. 1B).
The use of FK506 and rapamycin afford relatively specific means of
controlling protein activity in vivo. These small molecules share a nearly unique mechanism of action in that they generate large
and specific protein-protein interfaces that simulate normal protein-protein interactions. Genome-wide analysis revealed that FK506
and rapamycin each altered the expression of less than 0.5% of yeast
genes (10).2 By
contrast, temperature shifts, which have been used traditionally to
regulate protein activity in vivo, alter the expression of about 600 (~10%) yeast genes (11).
Delayed Silencing of Transcription following Recruitment and
Dissociation of the Activation Domain--
In cells expressing the
Gal4BD-FKBP12 and Gal4AD-CN fusions, FK506 activated transcription of
the endogenous GAL1 gene and an integrated
GAL1-HIS3 gene over a period of about 90 min (Fig. 2, A and B). These
kinetics appeared surprisingly slow but in fact closely corresponded to
the rate at which galactose induces transcription from the
GAL1 promoter under physiologic conditions (12, 13).
Importantly, rapamycin-mediated recruitment of an activation domain
showed similar kinetics of transcriptional induction, demonstrating
that rapamycin rapidly enters cells and binds Gal4BD-FKBP12 (see Fig. 4
and data not shown). Other studies also suggest that rapamycin crosses
membranes and forms complexes with its binding proteins within minutes
of its addition to medium (14).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
Residual transcriptional activity following
initiation of transcription and subsequent dissociation of the
activation domain. A, YDF6 expressing Gal4BD-FKBP12 and
Gal4AD-CN was treated with 50 ng/ml FK506. After 180 min, a 300-fold
weight excess of rapamycin was added to the culture. The experimental
protocol is shown schematically. Aliquots of cells were removed at the
indicated times, and HIS3 and GAL1 mRNA
levels were measured by Northern blotting. mRNA levels were also
determined in cells treated with rapamycin only for 180 min (rap
only). An endogenous HIS3 message (h) was
measured to control for RNA loading. B, mRNA levels were
quantitated by PhosphorImager analysis and plotted as mRNA levels
relative to untreated cells. Message levels were corrected for RNA
loading. The squares and diamonds indicate
HIS3 and GAL1 mRNA levels, respectively,
following treatment with 15 µg/ml rapamycin only. The predicted curve
represents the expected HIS3 mRNA levels if, following
activation domain dissociation, transcription ceased, given the
half-lives of the mRNAs (5 min) and the FKBP-FK506-CN complexes (5 min). C, YDF6 expressing Gal4BD-FKBP12 and Gal4AD-CN was
treated with 50 ng/ml FK506 for 30 min. A 300-fold weight excess of
rapamycin was then added to half of the culture (t = 0'). Aliquots of cells were removed at the indicated times following
addition of rapamycin, and HIS3 mRNA levels were
measured by Northern blotting. mRNA levels were also measured from
cells treated with rapamycin for 105 min in the absence of FK506
(rap only).
|
|
Once transcriptional activation by FK506 reached a steady state,
treatment with rapamycin to dissociate the activation domain rapidly
reduced GAL1 and HIS3 mRNA levels. Because
the GAL1 and HIS3 messages have extremely short
half-lives in yeast (<5 min; see Fig. 5C (15, 16)),
measuring the levels of these two messages provided accurate
assessments of the ongoing rates of transcription of both genes.
Addition of rapamycin prior to steady state activation both blocked
maximal activation and reduced mRNA levels (Fig. 2C). In
this case, the accumulation of message immediately following rapamycin
addition most likely reflected the time required for rapamycin to
dissociate FK506-mediated interactions (see below). Thus, consistent
with previous studies (1), these results confirmed that activators play
a continuous role in maintaining activated transcription.
Interestingly, we consistently observed the persistence of a reduced
level of transcription following extended rapamycin treatment, suggesting that promoters do not immediately return to their basal, inactive states following activation domain dissociation (Fig. 2). This phenomenon is quantitated in Fig. 2B. After
treatment with rapamycin, transcription of GAL1 and
HIS3 decayed slowly with a t1/2 of
approximately 50 min. The promoters returned eventually to their
inactive states, but the observed declines in HIS3 and
GAL1 transcriptional activity were delayed significantly
relative to that expected if transcription ceased following activation
domain dissociation (for the predicted curve, see dotted
line in Fig. 2B). The expected kinetics, which predict
a 90% reduction in mRNA levels within 30-40 min, reflect both the
half-life of the messages and the known kinetics of dissociation of the
FKBP-FK506-calcineurin complex (see Fig. 4). The concentrations of
rapamycin used to compete with FK506 completely blocked FK506-induced transcription (data not shown and Ref. 1), and the Gal4BD-FKBP12 fusion
did not activate transcription in the absence of FK506 (Fig.
3A). Thus we set out to
determine whether this residual transcriptional activity truly
persisted in the absence of the activation domain.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Residual transcription in the absence of
rapamycin-induced transcription. A, YSB7 expressing
Gal4BD-FKBP12 and Gal4AD-CN was transformed with a plasmid
overexpressing the FRB domain of Tor1 (+FRB) or an empty
control plasmid (no FRB). After treating the cells for
19 h with no drug, 50 ng/ml FK506, or 15 µg/ml rapamycin, cells
were assayed for -galactosidase activity. B, cells
expressing FRB (+FRB) or not (no FRB) were
treated with 50 ng/ml FK506 for 60 min. A 300-fold weight excess of
rapamycin was then added (t = 0'). The experimental
protocol is shown schematically. Aliquots of cells were removed at the
indicated times following addition of rapamycin, and HIS3
mRNA levels were measured by Northern blotting. mRNA levels
were also measured from untreated cells (no drug) and cells
treated with rapamycin for 105 min in the absence of FK506 (Rap
only). The double bands in the +FRB lanes
are due to more extensive separation of these RNA samples. An
endogenous HIS3 message (h) was measured to
control for RNA loading.
|
|
Given the ability of Gal4BD-FKBP12-rapamycin to bind the Tor proteins,
the persistence of residual transcription following rapamycin treatment
could have resulted from recruitment of a cryptic activation domain(s)
in these or related proteins. Indeed, assays for
-galactosidase
activity, which are significantly more sensitive than Northern blotting
for detecting expression, revealed a low level of transcriptional
activity in cells treated with rapamycin (Fig. 3A).
To determine whether residual transcription following activator
dissociation could have been the result of rapamycin-induced recruitment of Tor or other proteins, we overexpressed the FRB domain
of Tor1. This domain of Tor1 (amino acids 1765-2158) renders wild-type
cells resistant to rapamycin, most likely by competing with the
full-length Tor proteins for binding to FKBP-rapamycin (17). The same
domain of the highly homologous Tor2 protein fails to activate
transcription when fused directly to the Gal4 DNA-binding domain (18).
Thus FRB overexpression should compete with any potential activators
for binding to Gal4BD-FKBP12-rapamycin without stimulating
transcription. As predicted, overexpressing FRB eliminated the low
level of transcription induced by rapamycin (Fig. 3), indicating that
FKBP-rapamycin does not interact with activators at sites other than
the FRB-binding site. Despite FRB overexpression, however, residual
transcription persisted following transcriptional activation with FK506
and subsequent treatment with excess rapamycin (Fig. 3B).
Residual transcription was also observed when cells were washed to
remove FK506 without adding rapamycin (see Fig. 7B). Thus,
residual transcriptional activity was not due to recruitment of an
activator by rapamycin.
Rapamycin Rapidly Dissociated FKBP-FK506-Calcineurin Complexes at
Promoters in Vivo--
FK506 was chosen for activation domain
recruitment because of the short half-lives of the interactions it
generates. In studies with purified proteins, the half-life of the
FKBP-FK506-calcineurin complex has been estimated to be less than 5 min.3 However, interactions
with other cellular proteins in vivo or the effects of DNA
binding by Gal4BD-FKBP12 could have altered the dissociation kinetics
under the conditions of our experiments. These influences on the
stability of FKBP-FK506-calcineurin complexes could have unexpectedly
prolonged the association of the activation domain following rapamycin
treatment and thus sustained transcription following rapamycin
treatment as a result of incomplete dissociation of the Gal4AD-CN
fusion from Gal4BD-FKBP12. To address this possibility and confirm the
half-life of FK506-driven interactions, the kinetics of dissociation of
the FKBP-FK506-calcineurin complex were determined in
vivo.
To measure the stability of FKBP-FK506-calcineurin complexes,
Gal4BD-FKBP12 was expressed with two additional proteins: a version of
calcineurin lacking an activation domain and a fusion between the Gal4
activation domain and an FKBP-rapamycin-binding domain (FRB-AD).
Calcineurin was expressed in excess of Gal4BD-FKBP12 (data not shown),
and high concentrations (250 ng/ml) of FK506 were used to saturate
Gal4BD-FKBP12 in complexes with calcineurin. Because of the lack of an
activation domain on calcineurin, FK506 did not activate transcription.
When rapamycin was added, it competed with FK506 for binding to
Gal4BD-FKBP12, thereby displacing calcineurin and concomitantly
recruiting FRB-AD to activate transcription. Thus, monitoring
transcriptional activity following rapamycin addition provided a means
of determining the rate at which rapamycin dissociated the complex of
FK506, calcineurin, and Gal4BD-FKBP12.
Pretreatment with FK506 introduced an approximately 15-min delay in
transcriptional induction by rapamycin (Fig.
4). This delay represented the time
required for rapamycin to displace FK506 and calcineurin. These data
predicted a half-life of approximately 5 min for the
FKBP-FK506-calcineurin complex in vivo, consistent with the
rate of dissociation of the complex measured in vitro. In
cells not overexpressing calcineurin, FK506 did not detectably delay
rapamycin-induced transcription (Fig. 4), consistent with the short
half-life of the FKBP-FK506 interaction (<2 min).3 Our
measurement probably overestimated the actual time required for the
in vivo dissociation of calcineurin because activation domains function synergistically to activate transcription from promoters with multiple binding sites (19). Thus, before significant transcription would be induced by rapamycin-mediated activator recruitment, most of the four Gal4-binding sites in the promoter would
need to be cleared of FK506 and calcineurin. The parallel nature of the
two curves for cells overexpressing calcineurin indicated that
essentially all Gal4 sites were occupied by FRB-AD prior to detectable
transcriptional induction.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 4.
Rapid dissociation of FKBP-FK506-calcineurin
complexes in vivo. A, YSB7 expressing
Gal4BD-FKBP12 and a Gal4AD-FRB fusion was transformed with a plasmid
overexpressing murine calcineurin A and yeast calcineurin B
(+CN) or an empty control plasmid (no CN).
Following a 1-h pretreatment with (+FK506) or without
( FK506) 250 ng/ml FK506, 1.5 µg/ml rapamycin was
added (t = 0'). At this concentration of rapamycin,
FK506 did not inhibit transcriptional activation when cells were
treated with the two drugs simultaneously (data not shown). The
experimental protocol is shown schematically. Aliquots of cells were
removed at the indicated times following addition of rapamycin, and
GAL1 mRNA levels were measured by Northern blotting. An
endogenous HIS3 message (h) was measured to
control for RNA loading. B, message levels were quantitated
by PhosphorImager analysis and corrected for relative RNA loading. Fold
activation was measured as GAL1 mRNA levels relative to
untreated cells.
|
|
The short half-lives of these interactions are consistent with the
observation that FK506 does not induce any stabilizing conformational
changes in either FKBP or calcineurin (9). Furthermore, our studies
demonstrated that DNA binding by Gal4BD-FKBP12 did not significantly
alter the rate of dissociation the FKBP-FK506-calcineurin complex and
also that endogenous yeast proteins did not stabilize this complex
in vivo. Importantly, these kinetic studies utilized the
same protein domains used for activator recruitment by FK506. Thus, the
rate of dissociation of the FKBP-FK506-calcineurin complex in these
experiments was subject to the same influences that DNA-binding proteins and/or endogenous yeast proteins might have had during activation domain recruitment by FK506. These results strongly suggest
that extended periods of rapamycin treatment quantitatively displaced
Gal4AD-CN from the promoters.
The experiments presented in Fig. 4 would have been unable to detect
the persistence of a small fraction of calcineurin on promoters
following rapamycin treatment, because sufficient FRB-AD had been
recruited to fully activate transcription. A similar small amount of
the Gal4AD-CN fusion could have remained associated with promoters when
rapamycin was used to dissociate the activation domain. However, the
synergistic nature of activator function (19) requires that most of the
Gal4 sites on the promoter be occupied to induce transcription and
therefore suggests that persistence of a small fraction of Gal4AD-CN at
the promoter following rapamycin treatment would be insufficient to
activate significant levels of transcription. Furthermore,
transcription maintained by the presence of a small fraction of
Gal4AD-CN would be expected to display the functional properties of
activated transcription, which, as shown below, was not the case.
Persistence of transcription in a subpopulation of cells, such that a
fraction of cells differentially maintained high level gene expression,
is unlikely because expression of green flourescent protein at the
single-cell level varied evenly across the entire population of cells
in response to treatments similar to those used in the studies
described above (data not shown). Unfortunately, the prolonged
half-life of green flourescent protein precluded single-cell analysis
of the rate at which transcription shuts off following rapamycin treatment.
Functional Distinction between Activated and Residual
Transcription--
We began to investigate the nature of the
persistent transcriptional activity by comparing the abilities of
glucose to repress activated and residual transcription. Adding glucose
to the growth medium rapidly represses transcription from the
GAL1 promoter through cis-acting sites in the
upstream repressing sequence (12, 20). Thus, in the yeast strains used
in these experiments, glucose directly influences the activities of
promoters regulated by Gal4BD-FKBP12 and Gal4AD-CN.
In FK506-treated cells, where the activation domain was present on
promoters, glucose efficiently repressed GAL1 mRNA
levels (Fig. 5, A, compare
lane 1 with lane 2, and B). The level
of glucose-mediated repression was consistent with that seen in other
studies (12). If, however, cells were treated with rapamycin to
dissociate the activation domain, glucose was much less efficient in
repressing GAL1 expression (compare lane 3 with
lane 4). Consistent with inefficient glucose-mediated
repression of residual transcription, the presence or absence of
glucose did not significantly alter the kinetics with which
transcriptional activity decayed following activation domain
displacement (data not shown). As expected, transcription of the
GAL1
HIS3 gene, whose promoter lacked the upstream repressing sequence, resisted repression by glucose in both
the presence and absence of rapamycin.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 5.
Glucose-mediated repression of activated but
not residual transcription. A, YDF6 (MIG1)
expressing Gal4BD-FKBP12 and Gal4AD-CN was grown in raffinose medium
and treated with 50 ng/ml FK506 for 45 min. Half of the culture was
then treated with a 300-fold weight excess of rapamycin for 50 min
while the other half was not treated with rapamycin. Glucose (+) or
raffinose ( ) was then added to a 2% final concentration for 30 min.
The experimental protocol is shown schematically. Cells were harvested,
and GAL1 and HIS3 mRNA levels were measured
by Northern blotting. GAL1 and HIS3 mRNA
levels were also measured in YSB9 (mig1, ) that was
treated similarly with the exception that cells were not treated with
rapamycin (lanes 7 and 8). An endogenous
HIS3 message (h) was measured to control for RNA
loading. B, GAL1 message levels were quantitated
by PhosphorImager analysis and corrected for RNA loading and the extent
of activation by comparison with HIS3 mRNA levels. Fold
repression was determined by comparing GAL1 mRNA levels
in glucose- and raffinose-treated cells. Standard error is shown.
C, YSB6 (GAL4 TOR1-1) was grown for >12 h in
galactose. Cells were treated with 15 µg/ml rapamycin or left
untreated for 50 min. Glucose was then added to a 2% final
concentration (t = 0'). The experimental protocol is
shown schematically. Aliquots of cells were removed at the indicated
times following addition of glucose, and GAL1 mRNA
levels were measured by Northern blotting.
|
|
Glucose repression occurs through a signaling pathway that activates
the function of the Mig1 transcriptional repressor at the upstream
repressing sequence. Glucose may have failed to repress residual
GAL1 transcription because rapamycin interfered with the
cellular responses to glucose. Also, rapamycin may have stabilized the
GAL1 message, thereby interfering with the detection of
transcriptional repression. These potential effects of rapamycin were
addressed using yeast that possess the physiologic GAL1
regulatory machinery. We found that adding glucose to cells grown in
galactose reduced GAL1 message levels at the same rate and
to the same extent in untreated and rapamycin-treated cells (Fig.
5C). Thus, rapamycin did not alter the ability of the cells
to repress GAL1 expression in response to glucose or prolong
the half-life of GAL1 mRNA.
The differential repression of activated and residual transcription in
response to glucose distinguishes these two types of transcriptional
activity. If residual transcription merely represented low level
activated transcription because of, for example, incomplete dissociation of the activation domain, then glucose would have been
expected to repress both types of transcription with similar efficiencies. In fact, as will be shown below (see Fig. 7B),
glucose would have repressed transcription driven by incomplete
activation domain dissociation more effectively than fully activated
transcription. These results demonstrate that activated and residual
transcription possess different molecular properties, consistent with
the conclusion that activated transcription occurs in the presence of
the activation domain whereas residual transcription occurs in the
absence of the activation domain.
Despite a reduced response to glucose, a small amount of
repression by glucose was seen in rapamycin-treated cells
(Fig. 5, A, compare lane 3 with lane
4, and B). Comparing glucose repression in wild-type
(MIG1) and mig1
strains revealed that glucose
repressed residual transcription in MIG1 cells to the same
degree it repressed activated transcription in mig1
cells
(Fig. 5A, compare lane 7 with lane 8,
and B). These results indicate that this level of repression
represents promoter-independent effects of glucose on GAL1
message levels. Furthermore, these data suggest that the inefficiency
with which glucose repressed residual transcription stemmed
specifically from the inability of Mig1 to repress this type of transcription.
Passage through the Cell Cycle Failed to Erase Residual
Transcription--
We also examined the effects of passage through
various stages of the cell cycle on the rates of transcription
following activation domain dissociation. DNA replication and mitosis
influence the regulation of transcription, such that movement through
these phases of the cell cycle can render promoters receptive or
resistant to signals from transcription factors (21-23). If
replication or mitosis erased the effects of activator functions that
persist following its dissociation from promoters, then the residual
transcriptional activity would be silenced at these stages of the cell cycle.
The effects of cell cycle events on residual transcription were
assessed by establishing a synchronously dividing population of cells
and measuring the rates of transcription as the cells divided. Cells
were treated with FK506 to activate transcription and
-factor to
arrest the cell cycle. Rapamycin was then added to dissociate the
activation domain, and cells were either released from cell cycle
arrest or held in G1 phase with
-factor. Progression through the cell cycle was monitored by measuring CLN1
mRNA levels at different times (Fig.
6). CLN1 expression is limited
to the G1 and S phases of the cell cycle and peaks in late
G1 (24). Cells released from
-factor generated two peaks
of CLN1 expression, reflecting passage through one complete
cell division and a second round of DNA replication.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 6.
Passage through the cell cycle fail to erase
residual transcription. YDF6 expressing Gal4BD-FKBP12 and
Gal4AD-CN was treated with 50 ng/ml FK506 to activate transcription and
-factor to arrest cell division. After 3 h, cells were washed
and incubated with (+) or without ( ) -factor to maintain cell
cycle arrest or release cells into synchronous progression through the
cell cycle, respectively. Immediately after washing, a 300-fold weight
excess of rapamycin was added to both cultures. The experimental
protocol is shown schematically. Total RNA was isolated at the
indicated times following rapamycin addition, and CLN1 and
HIS3 mRNA levels were measured by Northern blotting.
Message levels were also measured in cells grown in the absence of
-factor and FK506 (asyn). An endogenous HIS3
message (h) was measured to control for RNA loading.
|
|
Rapamycin reduced the rate of transcription with the same kinetics in
cells arrested with
-factor as in cells dividing synchronously, as
shown by the similar reductions in HIS3 message levels over time in both populations (Fig. 6). The dividing cells were followed through two rounds of DNA synthesis, and thus events taking place shortly after
-factor release, which may have preceded complete activation domain dissociation, were assessed during the early phases
of the second cell division. These results demonstrated that DNA
replication, mitosis, and other cell cycle events failed to
significantly influence the rate at which transcription shuts off
following dissociation of the activation domain. The data also
highlight the fact that, when activator function is disrupted specifically, transcription persists through multiple cell divisions.
Activator-dependent Transcriptional Repression by
Ssn6-Tup1--
In the yeast strains used in these experiments, glucose
repressed GAL1 expression through the actions of Mig1, and
Mig1 repressed transcription by recruiting the general transcriptional
repressor, Ssn6-Tup1, to the promoter (15, 20, 25, 26). Thus, the findings that glucose inefficiently repressed residual transcription and that Mig1-dependent repression, specifically, appears
to be impaired indicated that repression by Ssn6-Tup1 may be defective under these conditions.
The observation that Ssn6-Tup1 is ineffective at repressing residual
transcription suggests that repression by this complex requires the
presence of the activation domain at the promoter. To test the
activator dependence of Ssn6-Tup1 directly, a means of specifically and
inducibly localizing the repressor was used to direct co-occupancy or
order of addition of an activator and Ssn6-Tup1 at promoters in
vivo (Fig. 1B). The FRB domain of FRAP was joined to
SSN6, and rapamycin was used to recruit FRB-Ssn6 to
Gal4BD-FKBP12. Because localizing Ssn6-Tup1 to promoters suffices for
transcriptional repression by this complex (27, 28), treatment with
rapamycin repressed expression from promoters containing Gal4-binding
sites. In cells expressing the Gal4AD-CN and FRB-Ssn6 fusion proteins,
FK506 was used to initiate transcription by recruiting the activation
domain. Following transcriptional induction, the addition of rapamycin
both displaced the activator and recruited FRB-Ssn6. The promoter
driving HIS3 contained four Gal4-binding sites, and, as
shown above, approximately 15 min of rapamycin treatment are required
to completely dissociate FK506 and calcineurin from Gal4BD-FKBP12.
Hence, the addition of rapamycin resulted in a brief period of
co-occupancy by the two fusion proteins, allowing Ssn6-Tup1 to act in
the activator's presence. In a second approach, an order of addition
was performed by first washing FK506 away from cells to dissociate the
activation domain and subsequently adding rapamycin to recruit
Ssn6-Tup1 in the absence of the activation domain. Comparison of these
two experimental regimens revealed that rapamycin repressed
transcription significantly more efficiently when it was added directly
than when it was added following a wash (Fig.
7A, compare lanes 1 and 2 with lanes 3 and 4). These data
confirmed the observations from the studies presented in Fig. 5, which
showed that Ssn6-Tup1-dependent repression by glucose
depended on the presence of the activator.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 7.
Activator-dependent repression by
a FRB-Ssn6 fusion. A, YSB7 expressing Gal4BD-FKBP12,
Gal4AD-CN, and FRB-Ssn6 was treated with 100 ng/ml FK506 for 2.5 h. Half of the cells were washed one time and resuspended in fresh
medium for 1 hr (wash, activator). The other
half of the cells were spun, but the medium was not changed
(+FK, +activator). Each of these two cultures was
split again, and half the cells were treated with 15 µg/ml rapamycin
for 50 min (+Ssn6) while the other half was incubated
without rapamycin ( Ssn6). The experimental protocol is
shown schematically. Cells were then harvested, and HIS3
mRNA levels were determined by Northern blotting and quantitated by
PhosphorImager analysis. Levels of an endogenous HIS3
message (h) were used to correct for RNA loading. Fold
repression was determined by comparing cells treated with and without
rapamycin. Standard error is shown. B, YSB7 expressing
Gal4BD-FKBP12, Gal4AD-CN, and FRB-Ssn6 was grown in raffinose medium
and treated with 100 ng/ml FK506 for 1 h. Half of the cells were
washed one time and resuspended in fresh medium for one hour
(wash). The other half of the cells were spun, but the
medium was not changed. Each of these two cultures was split again, and
either glucose (+glucose) or raffinose
( glucose) was added to a 2% final concentration for 30 min. Cells that had been washed were also treated with 2% glucose and
15 µg/ml rapamycin (+rapamycin, +glucose).
C, YSB7 expressing Gal4BD-FKBP12 and Gal4AD-CN was grown in
glucose or raffinose medium for >12 h. Following treatment with
increasing concentrations of FK506 for 3 h, cells were assayed for
-galactosidase activity. Fold repression was determined by comparing
-galactosidase activity from cells grown in glucose with that from
cells grown in raffinose.
|
|
Control experiments confirmed that similar to treatment with rapamycin,
washing FK506 away from cells generated residual transcriptional activity. Cells that had been washed or treated with rapamycin showed
similar levels of residual GAL1 and HIS3
transcription, and the transcriptional activity persisting after
washing was resistant to repression by glucose (Fig. 7B).
Furthermore, repression by glucose was not enhanced by additionally
recruiting FRB-Ssn6 with rapamycin (Fig. 7B). Similar
experiments suggested that the level of repression by FRB-Ssn6
following washing in Fig. 7A was most likely because of
incomplete removal of FK506 (data not shown). FRB alone did not repress
transcription in response to rapamycin (data not shown).
Inverse Relationship between Strengths of Activation and
Repression--
An alternative explanation for the apparent activator
dependence of Ssn6-Tup1 is that the repressor dictates a defined, low level of transcription. If residual transcriptional activity matches or
falls below that level, Ssn6-Tup1 would fail to further repress transcription irrespective of activator status. This kind of mechanism predicts that the extent of repression would be higher with stronger activation, because weak activators would stimulate transcription at
levels closer to the set point established by Ssn6-Tup1. To address
this possibility, we compared the extent to which Ssn6-Tup1 repressed
transcription from promoters of differing activities. Using
dose-dependent transcriptional activation by FK506, we
found that glucose, and therefore Ssn6-Tup1, repressed weak activation more efficiently than strong activation (Fig. 7C). These
data were consistent with previous studies using promoters of different strengths (e.g. GAL1 UAS and LEU2 UAS
(12)) but were inconsistent with the establishment of a transcriptional
set point by Ssn6-Tup1. In addition, these data showed that if, as
discussed above, residual transcription was driven simply by a fraction
of activation domains remaining associated with the promoters, then
Ssn6-Tup1 should have repressed residual transcription more effectively
than activated transcription.
Repression by a FRB-Sin3 Fusion in the Presence and Absence of the
Activation Domain--
The transcriptional repressor containing Sin3
and Rpd3 appears to inhibit transcription by deacetylating histones
(29, 30). Biochemical and genetic data strongly suggest that Sin3-Rpd3
and Ssn6-Tup1 exist as two distinct transcriptional repressors.
Therefore, to test the generality of activator-dependent
repression, we examined the ability of Sin3-Rpd3 to repress activated
and residual transcription. Similar to Ssn6-Tup1, localizing Sin3-Rpd3
to promoters suffices for transcriptional repression by this complex
(31, 32). Thus, SIN3 was fused to the FRB domain of FRAP,
and rapamycin was used to recruit Sin3-Rpd3 to promoters.
The abilities of Sin3-Rpd3 to repress transcription in the presence and
absence of the activation domain were determined by conducting
co-occupancy and order of addition experiments as described above.
Comparison of these two regimens demonstrated that, similar to
Ssn6-Tup1, Sin3-Rpd3 repressed activated transcription more efficiently
than residual transcription (Fig. 8,
compare lanes 1 and 2 with lanes 3 and
4). Thus, although both Ssn6-Tup1 and Sin3-Rpd3 rapidly
repressed transcription in the presence of the activation domain
(maximal repression was seen within 25 min of rapamycin treatment (data
not shown)), they both depended on the activator for maximal
repression.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 8.
Repression by a FRB-Sin3 fusion in the
presence and absence of the activator. YSB7 expressing
Gal4BD-FKBP12, Gal4AD-CN, and FRB-Sin3 was treated with 100 ng/ml FK506
for 2.5 h. Half of the cells were washed one time and resuspended
in fresh medium for 1 h (wash, activator).
The other half of the cells were spun, but the medium was not changed
(+FK, +activator). Each of these two cultures was
split again, and half the cells was treated with 15 µg/ml rapamycin
for 50 min (+Sin3) while the other half was incubated
without rapamycin ( Sin3). The experimental protocol is
shown schematically. Cells were then harvested, and HIS3
mRNA levels were determined by Northern blotting and quantitated by
PhosphorImager analysis. Levels of an endogenous HIS3
message (h) were used to correct for RNA loading. Fold
repression was determined by comparing cells treated with and without
rapamycin. Standard error is shown.
|
|
 |
DISCUSSION |
Residual Transcription following Activation Domain
Dissociation--
In general, three possibilities can explain the
persistence of transcription in cells treated with rapamycin to
displace the promoter-bound activation domain. First, an activator
other than the Gal4AD-CN fusion may have been present at the promoters
under these conditions. Second, Gal4AD-CN may have remained associated with the promoters despite rapamycin treatment. Third, transcription may have persisted in the absence of any activation domain. Our experimental evidence supports the conclusion that residual
transcription continued in the absence of an activation domain.
In cells treated with FK506, the simultaneous addition of rapamycin
blocked FK506-induced transcription (1). Thus FK506 was not generating
interactions with activators that could not be disrupted by rapamycin.
The Gal4BD-FKBP12 fusion failed to activate transcription in the
absence of FK506, demonstrating that this protein lacked an inherent
ability to drive transcription. Furthermore, the persistence of
transcription was not due to recruitment of an activation domain by
rapamycin (Fig. 3). These results demonstrate that an activator other
than the Gal4AD-CN fusion was not responsible for residual transcription.
FK506 and calcineurin dissociate from FKBP rapidly in vitro.
We confirmed the instability of these interactions and found that the
FKBP-FK506-calcineurin complex dissociated with a half-life of
approximately 5 min in vivo (Fig. 4). Detailed kinetic
analysis of the rate of dissociation of FK506 in mammalian cells
predicts a half-life of approximately 2 min (33). Analyses of the
properties of rapamycin further suggest that rapamycin enters cells and
binds Gal4BD-FKBP12 almost immediately following its addition to the growth medium (Fig. 4 and Ref. 14). Thus, several lines of evidence indicate that the half-life of FKBP-FK506-calcineurin complexes was
very brief and that extended periods of rapamycin treatment quantitatively dissociated the Gal4AD-CN fusion.
Finally, the finding that glucose and Ssn6-Tup1 failed to repress
residual transcription but efficiently repressed activated transcription distinguished the two types of transcription (Figs. 5 and
7). These results indicated that the residual transcription following
rapamycin treatment was not simply due to the persistence of an
activation domain on the promoter. Thus, disrupting the function of
transcriptional activators is not sufficient to rapidly inactivate gene expression.
Active Mechanisms to Return Promoters to Their Inactive
States--
Promoters are often controlled by transcription factors
whose activities are regulated in response to various stimuli, and changes in gene expression frequently coincide with the inactivation of
these transcriptional activators by mechanisms such as nuclear export,
degradation, and post-translational modification. Our results show that
disrupting the function of an activator slowly returns promoters to
their inactive states over a period of multiple cell divisions. These
findings suggest that tight regulation of transcription, such as occurs
for cell cycle-regulated genes, demands additional mechanisms to
silence transcription.
Chromatin presents one possible means of inactivating promoters.
Several promoters position nucleosomes specifically over critical
regulatory sequences, and in many cases the presence of these
structures correlates with promoter inactivity (34-36). Transcriptional activators disrupt these nucleosomes while inducing expression, which may suffice for transcriptional activity independent of further activator function (37). In this case, rapid reversal of
these structural changes in chromatin may be necessary for quickly
silencing promoters. However, activities capable of disrupting chromatin during transcriptional activation appear to impart relatively stable changes to the structures of nucleosomes (38-41), suggesting that some alterations in chromatin structure may not be rapidly reversed following removal of an activator. Furthermore, the Swi-Snf and SAGA chromatin remodeling complexes remain at a promoter despite dissociation of the activator (42). However, the activity of the yeast
Swi-Snf chromatin remodeling complex is required continuously to
maintain ongoing transcription (43). Thus, activities that counteract
the Swi-Snf complex, which functions during transcriptional activation
from the GAL1 promoter (43), could mediate rapid promoter inactivation.
Transcriptional repressors are known to counteract activators and
reduce gene expression. For many promoters, the combined activities of
transcriptional activators and repressors control expression (2-4,
44). In several of these examples, including genes regulated by the
yeast Ume6 and mammalian Max transcription factors, activators and
repressors appear to exchange with each other on the promoters they
regulate such that activators are dissociated and replaced by
repressors (2-4). Surprisingly, our data demonstrate that
the repressors, Ssn6-Tup1 and Sin3-Rpd3, lost activity in the absence
of the activator. Thus these repressors are poorly suited for rapidly
silencing gene expression following activator displacement. Instead,
recruitment of these repressors following activator disruption may
serve to prevent any further transcription driven by additional
activators. For example, in the context of a "permissive" chromatin
environment at the promoter of an actively transcribing gene,
preventing spurious transcriptional activation by transcription factors
binding to previously remodeled promoters may require monitoring by repressors.
Activator-dependent Repression by Ssn6-Tup1--
The
ability to recruit and dissociate the activation domain allowed us to
test the role of the activation domain in Ssn6-Tup1 function. Using
indirect, but physiologic means, as well as using rapamycin to directly
localize Ssn6-Tup1 at the GAL1 promoter, we found that
repression showed an unanticipated dependence on the presence of the
activation domain. This finding suggests the possibility that
activators and Ssn6-Tup1 share a common target(s) and that the
mechanism of repression is to neutralize the function of a target that
is recruited or otherwise activated by transcriptional activators. Thus
the presence of the activator at the promoter reveals the target of
Ssn6-Tup1 activity, but in the absence of the activator, this target is
not available for repression. The inverse relationship between levels
of activation and levels of repression (Fig. 7) further supports this
kind of functional interaction between activators and Ssn6-Tup1.
Increasing activator function could overwhelm repression by providing
the predominant influence over a common target. This inverse
relationship would not be expected if the activator and repressor
worked on independent effectors of transcription; instead, the extent
of repression would be constant despite varying levels of activation.
Nucleosomes represent potential targets for both activators and
Ssn6-Tup1. Transcriptional repression and nucleosome positioning by
Ssn6-Tup1 require the N terminus of histone H4 (45, 46). Similarly,
activation of GAL1 transcription requires the H4 N terminus
(47). Thus activators and Ssn6-Tup1 may convey competing signals
through their interactions with histone H4.
The transcriptional mediator complex, which associates with the
C-terminal domain of RNA polymerase II, is another potential target of
both activators and Ssn6-Tup1. Several mediator components are crucial
for efficient transcriptional activation from the GAL1/10
promoter and for efficient repression by Ssn6-Tup1 (48-51). One
current model of transcriptional activation suggests that activators
function by recruiting the mediator/RNA polymerase holoenzyme to
promoters (52). Consistent with the mediator also being a target
of repression, Ssn6-Tup1 repressed transcription activated by mediator
recruitment (data not shown). The mediator complex also contains Srb10
and Srb11, which encode a kinase whose activity is required for normal
levels of CTD phosphorylation. Intriguingly, point mutations that
disrupt kinase activity interfere with both transcriptional activation
and repression, suggesting that the level or specificity of Srb10-11
activity may be influenced by activators and Ssn6-Tup1 to regulate transcription.
In other studies, Ssn6-Tup1 has been shown to repress transcription
in vitro (53, 54). These results were interpreted as
evidence that Ssn6-Tup1 represses basal transcription, which by
definition occurs in the absence of any activator. However, these
experiments depended on Mcm1, a transcriptional activator, being bound
to the promoter and recruiting Ssn6-Tup1 to DNA. Thus, Ssn6-Tup1 may
have been repressing transcription activated by Mcm1, not basal transcription.
Transcriptional repression by Sin3-Rpd3 also depended on the presence
of the activator. Because Sin3-Rpd3 functions by deacetylating histones, displacing the activator and thereby inhibiting
acetyltransferase function may negate the effectiveness of Sin3-Rpd3 as
a repressor. The approximately 2-fold greater efficiency with which
Sin3-Rpd3 inhibited residual transcription compared with Ssn6-Tup1 may
reflect covalently associated acetyl groups remaining despite removal the acetyltransferase.
Strategy for Controlling Transcription Factors in Vivo--
By
generating fusion proteins between transcription factors and either
FKBP12, calcineurin, or FRB, we have demonstrated a general strategy
for regulating the activities of transcription factors in living cells
(1, 55, 56). This approach to the regulation and study of the function
of activators and repressors has recently been used to control
transcription of genes in whole animals (57). Order of addition and
co-occupancy experiments have previously been possible only in
vitro. The use of FK506 and rapamycin will facilitate these
experimental approaches in transgenic animals, where all of the
physiologic influences on complex processes such as transcription can
be taken into account. Furthermore, this approach is not limited to the
study of transcription factors, because the activities of many kinds of
proteins are regulated by physical interactions that can be
recapitulated by chemically induced proximity (58).
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 650-723-8391;
Fax: 650-723-1399; E-mail:
hf.grc@forsythe.stanford.edu.
Published, JBC Papers in Press, May 2, 2000, DOI 10.1074/jbc.M002991200
2
K. Vogel and G. R. Crabtree, unpublished data.
3
S. L. Schreiber, personal communication.
 |
ABBREVIATIONS |
The abbreviations used are:
FKBP, FK506-binding
protein;
FRB, FKBP-rapamycin-binding domain;
CN, calcineurin;
FRB, FK506/rapamycin binding domain of FRAP (FKBP12-rapamycin-associated protein).
 |
REFERENCES |
| 1.
|
Ho, S. N.,
Biggar, S. R.,
Spencer, D. M.,
Schreiber, S. L.,
and Crabtree, G. R.
(1996)
Nature
382,
822-826
|
| 2.
|
Bowdish, K. S.,
and Mitchell, A. P.
(1993)
Mol. Cell. Biol.
13,
2172-2181
|
| 3.
|
Bowdish, K. S.,
Yuan, H. E.,
and Mitchell, A. P.
(1995)
Mol. Cell. Biol.
15,
2955-2961
|
| 4.
|
Ayer, D. E.,
and Eisenman, R. N.
(1993)
Genes Dev.
7,
2110-2119
|
| 5.
|
Ptashne, M.,
and Gann, A.
(1997)
Nature
386,
569-577
|
| 6.
|
Fields, S.,
and Song, O.
(1989)
Nature
340,
245-246
|
| 7.
|
Liu, J.,
Farmer, J. D., Jr.,
Lane, W. S.,
Friedman, J.,
Weissman, I.,
and Schreiber, S. L.
(1991)
Cell
66,
807-815
|
| 8.
|
Chen, J.,
Zheng, X. F.,
Brown, E. J.,
and Schreiber, S. L.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4947-4951
|
| 9.
|
Griffith, J. P.,
Kim, J. L.,
Kim, E. E.,
Sintchak, M. D.,
Thomson, J. A.,
Fitzgibbon, M. J.,
Fleming, M. A.,
Caron, P. R.,
Hsiao, K.,
and Navia, M. A.
(1995)
Cell
82,
507-522
|
| 10.
|
Marton, M. J.,
DeRisi, J. L.,
Bennett, H. A.,
Iyer, V. R.,
Meyer, M. R.,
Roberts, C. J.,
Stoughton, R.,
Burchard, J.,
Slade, D.,
Dai, H.,
Bassett, D. E., Jr.,
Hartwell, L. H.,
Brown, P. O.,
and Friend, S. H.
(1998)
Nat. Med.
4,
1293-1301
|
| 11.
|
DeRisi, J. L.,
Iyer, V. R.,
and Brown, P. O.
(1997)
Science
278,
680-686
|
| 12.
|
Johnston, M.,
Flick, J. S.,
and Pexton, T.
(1994)
Mol. Cell. Biol.
14,
3834-3841
|
| 13.
|
Amon, A.,
Irniger, S.,
and Nasmyth, K.
(1994)
Cell
77,
1037-1050
|
| 14.
|
Barbet, N. C.,
Schneider, U.,
Helliwell, S. B.,
Stansfield, I.,
Tuite, M. F.,
and Hall, M. N.
(1996)
Mol. Biol. Cell
7,
25-42
|
| 15.
|
Flick, J. S.,
and Johnston, M.
(1990)
Mol. Cell. Biol.
10,
4757-4769
|
| 16.
|
Herrick, D.,
Parker, R.,
and Jacobson, A.
(1990)
Mol. Cell. Biol.
10,
2269-2284
|
| 17.
|
Zheng, X. F.,
Florentino, D.,
Chen, J.,
Crabtree, G. R.,
and Schreiber, S. L.
(1995)
Cell
82,
121-130
|
| 18.
|
Stan, R.,
McLaughlin, M. M.,
Cafferkey, R.,
Johnson, R. K.,
Rosenberg, M.,
and Livi, G. P.
(1994)
J. Biol. Chem.
269,
32027-32030
|
| 19.
|
Carey, M.,
Lin, Y. S.,
Green, M. R.,
and Ptashne, M.
(1990)
Nature
345,
361-364
|
| 20.
|
Flick, J. S.,
and Johnston, M.
(1992)
Genetics
130,
295-304
|
| 21.
|
Miller, A. M.,
and Nasmyth, K. A.
(1984)
Nature
312,
247-251
|
| 22.
|
Aparicio, O. M.,
and Gottschling, D. E.
(1994)
Genes Dev.
8,
1133-1146
|
| 23.
|
Barton, M. C.,
and Emerson, B. M.
(1994)
Genes Dev.
8,
2453-2465
|
| 24.
|
Wittenberg, C.,
Sugimoto, K.,
and Reed, S. I.
(1990)
Cell
62,
225-237
|
| 25.
|
Treitel, M. A.,
and Carlson, M.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
3132-3136
|
| 26.
|
Nehlin, J. O.,
Carlberg, M.,
and Ronne, H.
(1991)
EMBO J.
10,
3373-3377
|
| 27.
|
Keleher, C. A.,
Redd, M. J.,
Schultz, J.,
Carlson, M.,
and Johnson, A. D.
(1992)
Cell
68,
709-719
|
| 28.
|
Tzamarias, D.,
and Struhl, K.
(1994)
Nature
369,
758-761
|
| 29.
|
Rundlett, S. E.,
Carmen, A. A.,
Suka, N.,
Turner, B. M.,
and Grunstein, M.
(1998)
Nature
392,
831-835
|
| 30.
|
Taunton, J.,
Hassig, C. A.,
and Schreiber, S. L.
(1996)
Science
272,
408-411
|
| 31.
|
Wang, H.,
and Stillman, D. J.
(1993)
Mol. Cell. Biol.
13,
1805-1814
|
| 32.
|
Kadosh, D.,
and Struhl, K.
(1997)
Cell
89,
365-371
|
| 33.
|
Chow, F. S.,
Piekoszewski, W.,
and Jusko, W. J.
(1997)
Drug Metab. Dispos.
25,
610-616
|
| 34.
|
Wolffe, A. P.
(1994)
Cell
77,
13-16
|
| 35.
|
Almer, A.,
Rudolph, H.,
Hinnen, A.,
and Horz, W.
(1986)
EMBO J.
5,
2689-2696
|
| 36.
|
Axelrod, J. D.,
Reagan, M. S.,
and Majors, J.
(1993)
Genes Dev.
7,
857-869
|
| 37.
|
Struhl, K.
(1999)
Cell
98,
1-4
|
| 38.
|
Cote, J.,
Peterson, C. L.,
and Workman, J. L.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
4947-4952
|
| 39.
|
Logie, C.,
and Peterson, C. L.
(1997)
EMBO J.
16,
6772-6782
|
| 40.
|
Owen-Hughes, T.,
Utley, R. T.,
Cote, J.,
Peterson, C. L.,
and Workman, J. L.
(1996)
Science
273,
513-516
|
| 41.
|
Schnitzler, G.,
Sif, S.,
and Kingston, R. E.
(1998)
Cell
94,
17-27
|
| 42.
|
Cosma, M. P.,
Tanaka, T.,
and Nasmyth, K.
(1999)
Cell
97,
299-311
|
| 43.
|
Biggar, S. R.,
and Crabtree, G. R.
(1999)
EMBO J.
18,
2254-2264
|
| 44.
|
Sternberg, P. W.,
Stern, M. J.,
Clark, I.,
and Herskowitz, I.
(1987)
Cell
48,
567-577
|
| 45.
|
Roth, S. Y.,
Shimizu, M.,
Johnson, L.,
Grunstein, M.,
and Simpson, R. T.
(1992)
Genes Dev.
6,
411-425
|
| 46.
|
Cooper, J. P.,
Roth, S. Y.,
and Simpson, R. T.
(1994)
Genes Dev.
8,
1400-1410
|
| 47.
|
Durrin, L. K.,
Mann, R. K.,
Kayne, P. S.,
and Grunstein, M.
(1991)
Cell
65,
1023-1031
|
| 48.
|
Fassler, J. S.,
Gray, W.,
Lee, J. P., Yu, G. Y.,
and Gingerich, G.
(1991)
Mol. Gen. Genet.
230,
310-320
|
| 49.
|
Suzuki, Y.,
Nogi, Y.,
Abe, A.,
and Fukasawa, T.
(1988)
Mol. Cell. Biol.
8,
4991-4999
|
| 50.
|
Liao, S. M.,
Zhang, J.,
Jeffery, D. A.,
Koleske, A. J.,
Thompson, C. M.,
Chao, D. M.,
Viljoen, M.,
van Vuuren, H. J.,
and Young, R. A.
(1995)
Nature
374,
193-196
|
| 51.
|
Kuchin, S.,
and Carlson, M.
(1998)
Mol. Cell. Biol.
18,
1163-1171
|
| 52.
|
Keaveney, M.,
and Struhl, K.
(1998)
Mol. Cell
1,
917-924
|
| 53.
|
Herschbach, B. M.,
Arnaud, M. B.,
and Johnson, A. D.
(1994)
Nature
370,
309-311
|
| 54.
|
Redd, M. J.,
Arnaud, M. B.,
and Johnson, A. D.
(1997)
J. Biol. Chem.
272,
11193-11197
|
| 55.
|
Belshaw, P. J.,
Ho, S. N.,
Crabtree, G. R.,
and Schreiber, S. L.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
4604-4607
|
| 56.
|
Clipstone, N. A.,
Fiorentino, D. F.,
and Crabtree, G. R.
(1994)
J. Biol. Chem.
269,
26431-26437
|
| 57.
|
Ye, X.,
Rivera, V. M.,
Zoltick, P.,
Cerasoli, F., Jr.,
Schnell, M. A.,
Gao, G.,
Hughes, J. V.,
Gilman, M.,
and Wilson, J. M.
(1999)
Science
283,
88-91
|
| 58.
|
Klemm, J. D.,
Schreiber, S. L.,
and Crabtree, G. R.
(1998)
Annu. Rev. Immunol.
16,
569-592
|
| 59.
|
Leuther, K. K.,
and Johnston, S. A.
(1992)
Science
256,
1333-1335
|
| 60.
|
Schmitt, M. E.,
Brown, T. A.,
and Trumpower, B. L.
(1990)
Nucleic Acids Res.
18,
3091-3092
|
| 61.
|
Henikoff, S.,
Greene, E. A.,
Pietrokovski, S.,
Bork, P.,
Attwood, T. K.,
and Hood, L.
(1997)
Science
278,
609-614
|
| 62.
|
Nasmyth, K.,
Adolf, G.,
Lydall, D.,
and Seddon, A.
(1990)
Cell
62,
631-647
|
| 63.
|
O'Neill, E. M.,
Kaffman, A.,
Jolly, E. R.,
and O'Shea, E. K.
(1996)
Science
271,
209-212
|
| 64.
|
Timmerman, L. A.,
Clipstone, N. A.,
Ho, S. N.,
Northrop, J. P.,
and Crabtree, G. R.
(1996)
Nature
383,
837-840
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us &n